nach oben

Erschienen in:

30.08.2020 | Original Article

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

verfasst von: Sidar Copur, Dimitrie Siriopol, Baris Afsar, Melis C. Comert, Gizem Uzunkopru, Alan A. Sag, Alberto Ortiz, Adrian Covic, Daniel H. van Raalte, David Z. Cherney, Peter Rossing, Mehmet Kanbay

Erschienen in: Acta Diabetologica | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background and Aim

HbA1c, the traditional and current gold standard biomarker guiding diabetic management, has been scrutinized for low predictive value for patients with chronic kidney disease due to variables affecting erythrocyte number and turnover. Glycated albumin, the precursor to advanced glycation end products, reflects glycemic status over the preceding 2–3 week period and already outperforms HbA1c for glycemic monitoring. Our aim was to establish whether serum GA can be further used to predict mortality risk in dialysis patients with diabetes mellitus (DM)

Methods

We did systematic review of the literature in PubMed/Medline, Web of Science, Embase (Elsevier) and the Cochrane Central Register of Controlled Trials (Wiley) up to and including February 2020.

Results

This meta-analysis included 25,932 dialysis patients across 12 studies with maximum follow-up of 11 years. Higher GA levels were associated with the risk of all-cause mortality in dialysis patients with DM (HR 1.02, 95% CI 1.01 to 1.03, P < 0.001) irrespective of the type of dialysis, whereas higher GA was not associated with cardiovascular mortality (HR 1.03, 95% CI 0.99 to 1.06, P = 0.15) and cardiovascular events (both fatal and non-fatal) (HR 1.03, 95% CI 0.97 to 1.09, P = 0.31) in dialysis patients with DM.

Conclusion

Serum glycated albumin predicts all-cause mortality risk in dialysis patients with DM. The endpoints of cardiovascular mortality and cardiovascular events trended similarly, but did not reach significance at the current sample size.

Nur mit Berechtigung zugänglich

Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS et al (2016) Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 165(7):473–481PubMedPubMedCentral

Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F et al (2016) Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol 4(4):360–373PubMed

Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM (2006) Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70(8):1503–1509PubMed

Standards of medical care in diabetes (2015) summary of revisions. Diabetes Care. 38(Suppl):S4

National KF (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886

Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T et al (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol JASN 18(3):896–903PubMed

Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-Honda R, Noto H et al (2015) Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases. Clin Exp Nephrol 19(6):1179–1183PubMedPubMedCentral

Speeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J et al (2014) Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant 29(12):2167–2177PubMed

Ansari NA, Dash D (2013) Amadori glycated proteins: role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging Dis 4(1):50–56PubMed

10.

Tan ALY, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27(2):130–143PubMed

11.

Jun JE, Hur KY, Lee YB, Lee SE, Jin SM, Lee MK et al (2018) Glycated albumin predicts the development of early diabetic nephropathy in patients with type 2 diabetes. Diabetes Metab 44(2):178–180PubMed

12.

Cohen RM, Holmes YR, Chenier TC, Joiner CH (2003) Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 26(1):163–167PubMed

13.

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses Lancet 354(9193):1896–1900PubMed

14.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMed

15.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–34PubMed

16.

Higgins JP (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0: the cochrane collaboration

17.

Zhong CK, Zhong XY, Xu T, Zhang YH (2016) Measures of abdominal adiposity and risk of stroke: a dose-response meta-analysis of prospective studies. Biomed Environ Sci BES 29(1):12–23PubMed

18.

Chen CW, Drechsler C, Suntharalingam P, Karumanchi SA, Wanner C, Berg AH (2017) High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on Hemodialysis. Clin Chem 63(2):477–485PubMed

19.

Miyabe M, Kurajoh M, Mori K, Okuno S, Okada S, Emoto M et al (2019) Superiority of glycated albumin over glycated haemoglobin as indicator of glycaemic control and predictor of all-cause mortality in patients with type 2 diabetes mellitus receiving peritoneal dialysis. Ann Clin Biochem 56(6):684–691PubMed

20.

Hoshino J, Hamano T, Abe M, Hasegawa T, Wada A, Ubara Y et al (2018) Glycated albumin versus hemoglobin A1c and mortality in diabetic hemodialysis patients: a cohort study. Nephrol Dialysis Trans Off Publ Eur Dialysis Trans Assoc Eur Renal Assoc 33(7):1150–1158

21.

Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K et al (2008) Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 13(4):278–283 (Carlton, Vic.)PubMed

22.

Shafi T, Sozio SM, Plantinga LC, Jaar BG, Kim ET, Parekh RS et al (2013) Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 36(6):1522–1533PubMedPubMedCentral

23.

Lu C-L, Ma W-Y, Lin Y-F, Shyu J-F, Wang Y-H, Liu Y-M et al (2016) Glycated albumin predicts long-term survival in patients undergoing hemodialysis. Int J Med Sci 13(5):395–402PubMedPubMedCentral

24.

Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R et al (2007) Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Int Med 46(12):807–814 (Tokyo, Japan)

25.

Isshiki K, Nishio T, Isono M, Makiishi T, Shikano T, Tomita K et al (2014) Glycated albumin predicts the risk of mortality in type 2 diabetic patients on hemodialysis: evaluation of a target level for improving survival. Ther Apheresis Dial Off Peer-Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Ther 18(5):434–442

26.

Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K (2017) Serum albumin-adjusted glycated albumin as a better indicator of glycemic control in Type 2 diabetes mellitus patients with short duration of hemodialysis. Diabetes Res Clin Pract 130:148–153PubMed

27.

Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I (2019) Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci Rep 9(1):3320PubMedPubMedCentral

28.

Yajima T, Yajima K, Hayashi M, Yasuda K, Takahashi H, Yamakita N (2016) Serum albumin-adjusted glycated albumin is a better predictor of mortality in diabetic patients with end-stage renal disease on hemodialysis. J Diabetes Complicat 30(5):786–789

29.

Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY et al (2011) Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol CJASN 6(7):1635–1643PubMed

30.

Murea M, Moran T, Russell GB, Shihabi ZK, Byers JR, Andries L et al (2012) Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis. Am J Nephrol 36(5):488–496PubMed

31.

Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H et al (2018) The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 12(5):491–502PubMed

32.

Bloomgarden Z, Handelsman Y (2018) How does CKD affect HbA1c? J Diabetes 10(4):270PubMed

33.

Choi HY, Park SK, Yun GY, Choi AR, Lee JE, Ha SK et al (2016) Glycated albumin is independently associated with arterial stiffness in non-diabetic chronic kidney disease patients. Medicine 95(16):e3362PubMedPubMedCentral

34.

Kim IY, Kim MJ, Lee DW, Lee SB, Rhee H, Song SH et al (2015) Glycated albumin is a more accurate glycaemic indicator than haemoglobin A(1c) in diabetic patients with pre-dialysis chronic kidney disease. Nephrology 20(10):715–720 (Carlton, Vic.)PubMed

35.

Sany D, Elshahawy Y, Anwar W (2013) Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence. Saudi J Kidney Dis Trans Off Publ Saudi Center Organ Trans Saudi Arabia 24(2):260–273

36.

Selvin E, Rawlings AM, Lutsey PL, Maruthur N, Pankow JS, Steffes M et al (2015) Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation 132(4):269–277PubMedPubMedCentral

37.

Gan T, Liu X, Xu G (2017) Glycated albumin versus HbA1c in the evaluation of glycemic control in patients with diabetes and CKD. Kidney Int Rep 3(3):542–554PubMedPubMedCentral

38.

Peng F, Xia X, He F, Li Z, Huang F, Yu X (2015) The effect of glycated hemoglobin and albumin-corrected glycated serum protein on mortality in diabetic patients receiving continuous peritoneal dialysis. Peritoneal dialysis international. J Int Soc Perit Dial 35(5):566–575

39.

Fukami K, Shibata R, Nakayama H, Yamada K, Okuda S, Koga M (2015) Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis. J Diabetes Complicat 29(7):913–917

40.

Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J et al (1995) Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J Clin Investig 95(5):2338–2345PubMedPubMedCentral

41.

Cohen MP, Clements RS, Cohen JA, Shearman CW (1996) Glycated albumin promotes a generalized vasculopathy in the db/db mouse. Biochem Biophys Res Commun 218(1):72–75PubMed

42.

Qi C, Mao X, Zhang Z, Wu H (2017) Classification and Differential Diagnosis of Diabetic Nephropathy. J Diabetes Res 2017:8637138PubMedPubMedCentral

43.

Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic Kidney Disease: Challenges, Progress, And Possibilities. Clin J Am Soc Nephrol CJASN 12(12):2032–2045PubMed

44.

Kravchenko IV, Furalyov VA, Popov VO (2020) Glycated albumin stimulates expression of inflammatory cytokines in muscle cells. Cytokine 128:154991PubMed

45.

Martinez Fernandez A, Regazzoni L, Brioschi M, Gianazza E, Agostoni P, Aldini G et al (2019) Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free Radical Biol Med 144:245–255

46.

Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP (1998) Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int 53(3):631–638PubMed

47.

Coelho S, Rodrigues A (2014) Hemoglobin A1c in patients on peritoneal dialysis: how should we interpret it? Ther Apher Dial 18(5):375–382PubMed

48.

Watanabe Y, Ohno Y, Inoue T, Takane H, Okada H, Suzuki H (2014) Blood glucose levels in peritoneal dialysis are better reflected by HbA1c than by glycated albumin. Adv Perit Dial 30:75–82PubMed

Titel: Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker
verfasst von: Sidar Copur
Dimitrie Siriopol
Baris Afsar
Melis C. Comert
Gizem Uzunkopru
Alan A. Sag
Alberto Ortiz
Adrian Covic
Daniel H. van Raalte
David Z. Cherney
Peter Rossing
Mehmet Kanbay
Publikationsdatum: 30.08.2020
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 1/2021
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-020-01581-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background and Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

One hundred years ago: the dawning of the insulin era

Functional capacity and left ventricular diastolic function in patients with type 2 diabetes

Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study

Relative handgrip strength is inversely associated with the presence of type 2 diabetes in overweight elderly women with varying nutritional status

Nonalcoholic fatty liver disease and cardiovascular risk in severely obese adolescents